Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

Forest Laboratories

Status and phase: Terminated; Phase 3

Conditions: Diabetes Mellitus, Type II

Treatments: Drug: Dutogliptin; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00947557

DUT-MD-303

Details and patient eligibility

About

This study will evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background therapy of glimepiride with or without metformin.

Enrollment: 677 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes mellitus, diagnosed at least 3 months prior to Screening (Visit 1)
• BMI 20 to 48 kg/m2, inclusive
• HbA1c 7.0% - 10.0%, inclusive
• Age 18 to 85 years, inclusive

Exclusion criteria

• Currently on 3 or more oral antidiabetic drugs or insulin.
• Type 1 diabetes mellitus

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

677 participants in 2 patient groups, including a placebo group

Dutogliptin

Active Comparator group

Description:

Dutogliptin

Treatment:

Drug: Dutogliptin

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo